Clinical trial · Interventional
Sentinel Lymph Node Mapping in Rectal Cancer
Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to develop a technique that allows physicians to identify the first lymph nodes draining from a rectal tumor (the sentinel lymph nodes). Currently, there is no technique used to find these lymph nodes in the rectum during surgery and therefore many patients with rectal cancer need to undergo a total rectal resection. Dyes, tracers, imaging and a gamma probe will be used in this study during a standard minimally invasive transanal endoscopic surgery (TES) to try to locate these lymph nodes. If surgeons are able to locate these lymph nodes they will be removed during surgery. If the technique is successfully developed as a result of this research, it could help patients in the future with early stage rectal cancer by allowing doctors to see if their cancer has spread to the lymph nodes of the rectum without having to undergo a total rectal resection. These patients would then be able to undergo a TES combined with a lymph node dissection to gain more knowledge about the stage of their disease. This knowledge would then be used to determine if and what further treatment is necessary for the patient's rectal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Neoplasms | Rectal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dissection of sentinel lymph node(s) | Procedure | — | UNRESOLVED |
| Endoscopic injection of 99mTc-sulfur colloid | Other | — | UNRESOLVED |
| Endoscopic injection of ICG | Other | — | UNRESOLVED |
| Endoscopic injection of Spot | Other | — | UNRESOLVED |
| Endoscopic NIR imaging and gamma probe | Procedure | — | UNRESOLVED |
| Flexible sigmoidoscopy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Intraoperative sentinel lymph node mapping
- description
- Subjects will come to the OR and undergo a flexible sigmoidoscopy after induction of anesthesia and receive separate endoscopic injections of Spot (up to 5 cc), 99mTc-sulfur colloid (up to 0.5 mCi), and Indocyanine green (ICG) (1 ml). Patient will undergo the standard transanal endoscopic surgery (TES) to remove the rectal neoplasm, exposing the lymph node basin. The sentinel node(s) will be identified using a combination of the gamma probe and fluorescence imaging endoscopically, dissected out, and removed through a transanal approach.
- interventionNames
- Other: Endoscopic injection of 99mTc-sulfur colloid
- Other: Endoscopic injection of ICG
- Other: Endoscopic injection of Spot
- Procedure: Flexible sigmoidoscopy
- Procedure: Endoscopic NIR imaging and gamma probe
- Procedure: Dissection of sentinel lymph node(s)
Primary outcomes (2)
- measure
- 1st Phase: Detection rate of sentinel lymph node in first 6 patients
- timeFrame
- Throughout first phase of study, an average of 1 year.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult patients undergoing elective transanal endoscopic surgery (TES) at the University of Virginia for rectal neoplasm (polyp with high grade dysplasia, T1N0 tumors \< 3cm in the absence of poor pathologic features, patients that refuse radical resection) * Willing and able to give written informed consent Exclusion Criteria: * Patients less than 18 years of age * Women who are pregnant and/or breastfeeding * Prisoners * Unable to give written informed consent * Patients with any of the following: * Allergy to technetium, Spot and/or ICG * Allergy to iodides * Severe cardiac disease (hospitalization for cardiac disease in the last year, congestive heart failure, abnormal EKG) or renal disease (Creatinine \> 2.0 mg/dL) * Patients with medical contradictions or have potential problems complying with the requirements of the protocol, in the opinion of the investigator
References
Publications (0)
Data not yet available